Cincinnati Children’s Hospital is starting Phase 3 of its COVID-19 clinical trials after a promising Phase 1 and 2. Phase 1 and 2 clinical trial data tested the safety of two vaccines and their ability to have our bodies make an immune response. Phase 3 studies will focus more on how effectively the vaccines generate durable immunity against the SARS-CoV-2 virus that causes COVID-19.Tri-State residents between the ages of 18 and 85 can volunteer for Phase 3 clinical trials at Children’s.Children’s needs up to 1,000 participants. Participants are compensated for their time, health officials said. Health officials noted people are not given the virus, only a vaccine that includes a small part of the virus that does not cause COVID-19 disease. “For the vaccine studies to be as effective and impactful as possible, our study population at Cincinnati Children’s should accurately reflect the diverse population of the Tri-state region,” said Robert Frenck, MD, director of the Gamble Program at Cincinnati Children’s and the physician overseeing the studies. “We want these vaccines to be tested on and available to everyone who needs them, and that includes those communities at higher risk because of disparities in health care.”For more information or to sign up for the vaccine studies, click here or call 513-636-7699.
Cincinnati Children’s Hospital is starting Phase 3 of its COVID-19 clinical trials after a promising Phase 1 and 2.
Phase 1 and 2 clinical trial data tested the safety of two vaccines and their ability to have our bodies make an immune response.
Phase 3 studies will focus more on how effectively the vaccines generate durable immunity against the SARS-CoV-2 virus that causes COVID-19.
Tri-State residents between the ages of 18 and 85 can volunteer for Phase 3 clinical trials at Children’s.
Children’s needs up to 1,000 participants. Participants are compensated for their time, health officials said.
Health officials noted people are not given the virus, only a vaccine that includes a small part of the virus that does not cause COVID-19 disease.
“For the vaccine studies to be as effective and impactful as possible, our study population at Cincinnati Children’s should accurately reflect the diverse population of the Tri-state region,” said Robert Frenck, MD, director of the Gamble Program at Cincinnati Children’s and the physician overseeing the studies. “We want these vaccines to be tested on and available to everyone who needs them, and that includes those communities at higher risk because of disparities in health care.”
For more information or to sign up for the vaccine studies, click here or call 513-636-7699.